Conference Agenda
Overview and details of the sessions of this conference. Please select a date or location to show only sessions at that day or location. Please select a single session for detailed view (with abstracts and downloads if available).
|
Daily Overview |
| Session | |
|
CP9.1: Vaccines 10 min talks sponsored by Institute for Biomedicine and Glycomics, Griffith University Location: Lecture Theatre 2 Session Chair: Danielle Stanisic, Institute for Biomedicine and Glycomics, Griffith University Session Chair: Anouschka Akerman, The University of Queensland | |
    | |
Impact of malaria infection on priming and boosting immunity induced by a CAF01-adjuvanted whole parasite P. yoelii blood-stage malaria vaccine Institute for Biomedicine and Glycomics, Griffith University, Australia Introduction: Malaria remains a significant health problem. Globally, 282 million malaria cases and 610,000 malaria deaths occurred in 2024. The WHO recommends RTS,S/AS01 and R21-Matrix-M pre-erythrocytic vaccines to prevent malaria in children <5 yrs in moderate-to-high transmission settings. These vaccines are only partially effective. Evidence suggests that pre-erythrocytic vaccines are not boosted by natural malaria infection. We therefore assessed whether a whole-parasite blood-stage vaccine is more efficient in the presence of a malaria infection. Methods: Different groups of mice received a controlled malaria infection with P. yoelii before or after vaccination. Mice were vaccinated with three doses of either killed 105, 106 or 107 P. yoelii pRBCs formulated with the liposomal adjuvant, CAF01. Four weeks after the final vaccine dose or controlled malaria infection, mice from each group were challenged with homologous parasites. Results: A priming malaria infection did not provide additional protection against parasitaemia to mice that received 107 or 106 P. yoelii pRBCs in the vaccine; however, it provided additional protection to those vaccinated with a lower dose. Boosting vaccination with malaria infection enhanced control of parasitaemia in all vaccinated groups. Reducing parasite vaccine doses in the presence of infection would lower the cost of vaccinating populations. | |